Non-Traditional Therapies Could Fill Vital Mental Health Needs

- FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, March 2, 2021 /PRNewswire/ -- Non-traditional therapies are coming a long way from their stigmatized roots. Rising rates of serious mental health issues and unreliability of traditional mental health treatments have spurred research into treatment forms utilizing once stigmatized and criminalized drugs. The results have been promising enough that the pharmaceutical industry around therapeutic MDMA, ketamine, psilocybin, and other psychoactive substances is taking shape and gaining momentum. Non-traditional therapies are gaining government regulatory approval and, in some cases, even breakthrough therapy designations, and the companies moving this revolution forward like Numinus Wellness Inc. (TSXV:NUMI) (OTCPK:LKYSF), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceuticals (NYSE:TAK), Optimi Health (CSE:OPTI), and Tryp Therapeutics (CSE:TRYP) (OTCPK:TRYPF) are finding huge opportunity here.

Numinus Wellness Advances MDMA-Assisted Therapy

Integrated mental health company Numinus Wellness Inc. (TSXV:NUMI) (OTCPK:LKYSF) is one of the companies working to advance innovative treatments like psychedelic-assisted psychotherapy into safe, evidence-based, accessible solutions. Through its Numinus Health segment, the company delivers innovative treatments to address physical, mental, and emotional health, through clinics and virtual services, while Numinus R&D conducts implementation science, and Numinus Bioscience serves as the company's applied research and IP development lab.

In partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation, Numinus is conducting a single-arm, open-label, compassionate access trial for MDMA-assisted therapy for treatment of patients with post-traumatic stress disorder. On February 17, the company announced that the trial has made significant progress, successfully transitioning to the pre-implementation stage at Numinus's Vancouver clinic.

"We are excited to share an update on the progress of our MDMA compassionate access trial with the full recognition that existing therapies for PTSD are inadequate," Numinus CEO Payton Nyquvest said in the company's release. "At Numinus, we are pleased to help foster a promising regulatory landscape that will contribute to a better understanding that psychedelic-assisted psychotherapies are a viable, safe, and necessary avenue for expanding existing treatment options. We look forward to continued collaboration with MAPS PBC and will work together to provide those experiencing PTSD with more treatment options."